Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 17k
9 July 2019
E-002190-19
Question for written answer E-002190-19
to the Commission
Rule 130
Daniel Buda (PPE)

 Subject:  Limited access to new medicines

Currently, across Europe, life expectancy is 30 years higher compared to what it was a century ago, and this is due to investments in medical research. Unfortunately, in Romania, the research and health sectors are under-financed. Consequently, Romanians are among the last Europeans to have access to new medicines.

The impact of medical research translates into lives saved. In Western Europe, patients have access to an innovative medicine in less than 4 months after it has been authorised by the European Medicines Agency, while in Romania this procedure takes more than 3 years. The budget allocated for medicines in Romania does not even cover the current needs of Romanian patients, so that access to the latest generation treatments comes secondary.

What measures can the Commission take in order for Romanian citizens to have easier and quicker access to the innovative medicines available in Europe?

Original language of question: RO 
Last updated: 26 July 2019Legal notice